VAXNEUVANCE 30 MCG / 0.5 ML
PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 22F : 2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19A : 2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 14 : 2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 1 : 2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6A : 2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 33F : 2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9V : 2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 18C : 2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 4 : 2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 23F : 2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6B : 4 MCG / 0.5 ML CORYNEBACTERIUM DIPHTHERIAE CRM-197 PROTEIN : 30 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 5 : 2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 3 : 2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19F : 2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 7F : 2 MCG / 0.5 ML · DIN 02522403 · MERCK CANADA INC
Health Canada status: MARKETED
What is VAXNEUVANCE?
VAXNEUVANCE 30 MCG / 0.5 ML contains PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 22F : 2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19A : 2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 14 : 2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 1 : 2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6A : 2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 33F : 2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9V : 2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 18C : 2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 4 : 2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 23F : 2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6B : 4 MCG / 0.5 ML CORYNEBACTERIUM DIPHTHERIAE CRM-197 PROTEIN : 30 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 5 : 2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 3 : 2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19F : 2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 7F : 2 MCG / 0.5 ML. It is listed in the Health Canada Drug Product Database under DIN 02522403, held by MERCK CANADA INC, supplied as SUSPENSION for INTRAMUSCULAR administration. Health Canada currently lists it as marketed, status dated 02-Sep-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is VAXNEUVANCE used for?
VAXNEUVANCE® (Pneumococcal 15 - valent Conjugate Vaccine [CRM 197 Protein], adsorbed) is indicated for active immunization for the prevention of invasive disease (including sepsis, meningitis, bacteremic pneumonia, pleural empyema and bacteremia) caused by Streptococcus pneumoniae serotypes ( 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F ) in individuals 6 weeks of age and older . VAXNEUVANCE® may not prevent disease caused by S. pneumoniae serotypes that are not contained in the vaccine.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02522403 |
|---|---|
| Brand name | VAXNEUVANCE |
| Generic / active ingredient | PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 22F : 2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19A : 2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 14 : 2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 1 : 2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6A : 2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 33F : 2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9V : 2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 18C : 2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 4 : 2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 23F : 2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6B : 4 MCG / 0.5 ML CORYNEBACTERIUM DIPHTHERIAE CRM-197 PROTEIN : 30 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 5 : 2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 3 : 2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19F : 2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 7F : 2 MCG / 0.5 ML |
| Manufacturer | MERCK CANADA INC |
| Strength | 30 MCG / 0.5 ML |
| Dosage form | SUSPENSION |
| Route of administration | INTRAMUSCULAR |
| Schedule | Schedule D |
| ATC code | J07AL02 PNEUMOCOCCUS, PURIFIED POLYSACC.ANTIGEN CONJUGATED |
| AHFS class | 80:12.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 02-Sep-2022 |
| Original market date | 2022-09-02 00:00:00 |
How is it stored and handled?
null
How is it supplied?
Available in 1 or 10 prefilled syringe packages.
What can be used instead?
Other Canadian products sharing ATC code J07AL02 PNEUMOCOCCUS, PURIFIED POLYSACC.ANTIGEN CONJUGATED. 3 of 10 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| CAPVAXIVE | 4 MCG / 0.5 ML | SOLUTION | MERCK CANADA INC | MARKETED | DIN 02549891 |
| PREVNAR 20 | 2.2 MCG / 0.5 ML | SUSPENSION | PFIZER CANADA ULC | MARKETED | DIN 02527049 |
| PNEUMO 23 | 25 MCG / 0.5 ML | LIQUID | SANOFI PASTEUR LIMITED | CANCELLED POST MARKET | DIN 02231259 |
| PNEUMOVAX 23 | 25 MCG / 0.5 ML | SOLUTION | MERCK CANADA INC | CANCELLED POST MARKET | DIN 00431648 |
| PNEUMOVAX 23 -(5-DOSE) | 25 MCG / 0.5 ML | SOLUTION | MERCK CANADA INC | CANCELLED POST MARKET | DIN 02240632 |
| PNU-IMUNE 23 | 25 MCG / 0.5 ML | LIQUID | LEDERLE LABS, DIVISION OF AMERICAN CYANAMID CO | CANCELLED POST MARKET | DIN 02230175 |
| PREVNAR | 20 MCG / 0.5 ML | SUSPENSION | PFIZER CANADA ULC | CANCELLED POST MARKET | DIN 02244081 |
| PREVNAR 13 | 2.2 MCG / 0.5 ML | SUSPENSION | PFIZER CANADA ULC | CANCELLED POST MARKET | DIN 02335204 |
| SYNFLORIX | 3 MCG / 0.5 ML | SUSPENSION | GLAXOSMITHKLINE INC | CANCELLED POST MARKET | DIN 02320541 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.